ArticleRadiology and oncology2025
Value of ultrasound assessment of sarcopenia in patients with diffuse large B-cell lymphoma: a prospective study.
Article in Radiology and oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study investigated the clinical utility of ultrasound in diagnosing sarcopenia in patients with diffuse large B-cell lymphoma (DLBCL), focusing on muscle mass, strength, and physical fitness. PATIENTS AND
methodsA prospective analysis was conducted on 167 patients with DLBCL (88 with sarcopenia and 79 without). Muscle thickness (MT), cross-sectional area (CSA), and subcutaneous fat thickness (SFT) were measured using ultrasound at various anatomical sites. Diagnostic efficacy of muscle indices for sarcopenia was assessed using receiver operating characteristic (ROC) curves.
resultsPatients with sarcopenia exhibited significant reductions in MT and CSA across multiple muscle groups, including biceps brachii (BB), vastus intermedius (VI), and rectus femoris (RF) (all p ≤ 0.001). ROC analysis identified RF-CSA as the most effective indicator of sarcopenia, with an area under the curve (AUC) of 0.87, a sensitivity of 86%, and a specificity of 83% at a critical value of 7.08 cm
conclusionsUltrasound was a cost-effective and accessible diagnostic tool for identifying sarcopenia in DLBCL patients. Early detection through ultrasound can guide timely interventions and improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.